Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease

Inclusion Criteria: * Population with target to background ratio of 2.2 of the aorta or carotid artery on PET-CT Exclusion Criteria: * Current medical history of auto-immune disease/vasculitis, active inflammatory diseases, Recent (\<1 month prior to screening) or ongoing serious infection requiring IV antibiotic therapy. * Recent or current treatment with medications that may have a significant effect on plaque inflammation as measured by plaque TBR, including but not limited to: * Steroids for at least 6 weeks prior to baseline measurement and during study (with the exception of inhaled acute use steroids). * Biological based medicines (anti-TNF (ex. Infliximab), anti-IL-6 therapy (ex. Tocilizumab) or anti-IL-1 (ex. anakinra)) within 8 weeks before the baseline visit and during the study * No other disease modifying antirheumatic drugs (DMRADS) within 6 weeks of baseline and during study (such as cyclosporine, azatioprine, etc.) * Known systemic disorders such as hepatic, renal, hematologic, and malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study. * Changes in dose or frequency of doses at least 6 weeks prior to baseline measurement (unstable dosing) in angiotensin-converting enzyme (ACE) inhibitors (ACE-I) or angiotensin-receptor blockers (ARBs), non-statin lipid-modifying therapy, thiazolidinediones, inhaled steroids, or leukotriene modifying agents, nonsteroidal anti-inflammatory drugs (NSAIDS), and cyclo-oxygenase-2 inhibitors (COXIBs) * Standard contra-indications to MRI, 18FDG PET, and CT based on physicians experience and current practices * Current medical history of poorly controlled diabetes defined as hemoglobin A1c (HbA1c) \>7.5%. * Current medical history of drug or alcohol abuse within 12 months prior to screening. * History of anaphylaxis, anaphylactoid (resembling anaphylaxis) reactions, or severe allergic responses. * Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study. * Subject has planned cardiac surgery, PCI or carotid stenting, or major non-cardiac surgery during the course of the study period or for 14 days after the last treatment. * Use of any investigational drug in the 3 months prior to study drug administration. * Use of insulin or any oral anti-diabetic (except metformin) in the 30 days prior to baseline measurements. Those subjects who are taking metformin may be included in the study if they are on a stable dose for at least 4 weeks and have a HbA1c \<7.5%. * Any contraindications for corticosteroid infusions (for example, but not limited current infections or vaccinations)